2016 Symposium

2015 Symposium

2015 Agenda and Bios

2015 Symposium Photos

2014 Symposium

2014 Agenda and Bios

2013 Featured Talks

2013 Symposium Photos

Previous Symposia

2016 Symposium: Save the Date!


Thursday, February 25, 2016
8AM – 6PM | Goldberg Auditorium
UC San Diego Moores Cancer Center
La Jolla, California


Contemporary leaders of oncology are driven to redefine the notion of curative medicine by skillfully leveraging the power of collaboration to optimize everyone’s unique expertise and stretch research dollars in order to drive innovation. They are also changing clinical trial paradigms and emphasizing combination immunotherapy, new therapeutic modalities, and precision diagnosis. Already, as a result of these efforts, the oncology community can treat cancer patients and combat cancer at the molecular level.

The annual Industry/Academia Translational Oncology Symposium at Moores Cancer Center, now celebrating its 12th year, was created to support multi-modality collaborations and foster new partnerships in order to speed new therapies to patients. Each year the Symposium’s esteemed presenters from around the world, including clinicians, researchers, and top decision makers from industry and academia, attest to just how necessary it was for them to surmount multiple obstacles, in and out of the lab, in order to achieve success and help patients. The forum provides a platform for oncology innovators to highlight their interdisciplinary approach, as opposed to discussion on a specific type of cancer. Case study presentations showcase successful efforts, the challenges that they encountered, and the lessons they have learned from the process.


To address the need for dialogue amongst all leaders of cancer research, the Symposium promotes interaction and discussion throughout the entire program. Invited speakers give presentations that range in length, and include a keynote presentation, numerous presenters from faculty and industry, young investigator presentation, interactive discussion panels, and poster sessions, highlighting rapidly emerging cancer science. Discussions continue throughout breaks and lunch, and culminate in a networking reception. Additionally, a dinner consisting of Symposium speakers and sponsors held prior to the event creates an opportunity for introductions to be made and work to be discussed in a relaxed, collegial setting. Through the Symposium’s emphasis on translational oncology and drug development, we shepherd researchers and physicians to foster fruitful, ongoing relationships and partnerships with local, regional, and national biotechnology and pharmaceutical companies, ultimately resulting in curative therapies that advance global cancer treatment paradigms.


The field of oncology is brimming with innovators and investigators ready to blaze new pathways for bringing the most effective novel therapies out of the laboratory to the patients. Clinicians, researchers, and top decision makers are critical in the process of translation to deliver curative cancer therapies. Our goal is to unite these individuals and provide a forum through which they can network and collaborate, while celebrating the community’s successful efforts.


  • Immunotherapy
  • Precision medicine
  • New therapeutic approaches in numerous cancers
  • Orphan drug oncology indications
  • Innovative clinical trial modalities
  • Funding innovation


Dennis Slamon, MD, PhD

Director, Clinical/Translational Research
UCLA Jonsson Comprehensive Cancer Center

Please note: Additional speakers will be announced as they are confirmed.


Diego Alvarado, PhD

Associate Director of Research
Kolltan Pharmaceuticals

David Brenner, MD

UC San Diego School of Medicine

J. Silvio Gutkind, PhD

UC San Diego Moores Cancer Center

Catriona Jamieson, MD, PhD

UC San Diego Moores Cancer Center

Razelle Kurzrock, MD

UC San Diego Moores Cancer Center

Michael Pellini, MD

Chief Executive Officer
Foundation Medicine

Birgit Schoeberl

SVP, Head of Discovery

Craig Venter

Founder, Chairman, and CEO, J. Craig Venter Institute
Co-Founder, Executive Chairman, and Co-Chief Scientist, Synthetic Genomics Inc.
Co-Founder, Executive Chairman, and CEO, Human Longevity Inc.


San Diego provides an ideal environment for successful partnerships and collaborations: The intersection of academia, biomedical research, top-notch health care providers, and entrepreneurship allow innovation to abound. San Diego’s position as a global hub for biomedical innovation serves as a role model for translational oncology on a national level.

2015 Symposium Featured Talks

Please enjoy the featured talks below from our recent symposium. Thank you!

Please note: These videos are for private viewing only. Any unintended use of the videos without consent is prohibited.

Symposium Organizer Welcome

Ida Deichaite, PhD
UC San Diego Moores Cancer Center

Moores Cancer Center Welcome

Scott Lippman, MD
UC San Diego Moores Cancer Center

Dean, School of Medicine Welcome

David Brenner, MD
UC San Diego School of Medicine

Chancellor Welcome

Pradeep Khosla, PhD
UC San Diego

Finding the Money to Fund Translational Research

Rep. Scott Peters, Congressman
Bob Klein, Klein Financial Corporation

National Entrepreneurs Month Presented to the Roth Family

Presented by Rep. Scott Peters, Congressman

Duane Roth Award

Presented by Rep. Scott Peters, Congressman
Awarded to Brian Druker, MD, OHSU Knight Cancer Institute

Keynote Presentation: Imatinib as a Paradigm of Molecularly Targeted Cancer Therapies

Brian Druker, MD
OHSU Knight Cancer Institute

Drugging the Undrugable: KRAS

D. Lynn Kirkpatrick, PhD
PHusis Therapeutics

ePatients on the Front Lines: Precision Medicine, the FDA, and Me

Janet Freeman-Daily, MS, ENG
Patient Advocacy

Keynote Presentation: Cancer Genomics: Turning Discovery into Translation

Elaine Mardis, PhD
The Genome Institute
Washington University School of Medicine

Advancing the Utility of Clinic Sequencing for MDS

Rafael Bejar, MD, PhD
UC San Diego Moores Cancer Center

A More Beautiful Question

Brad Perkins, MD
Human Longevity

A novel bispecific antibody targeting EGFR and cMet with multiple mechanisms of action

Mark Anderson, PhD
Janssen Pharmaceuticals

Napoleon in Rags and the Language that he Used: the New World of Immunotherapy in Head and Neck Cancer

Ezra Cohen, MD
UC San Diego Moores Cancer Center

Melanoma Patients Path: Translations to the Clinic

Gregory Daniels, MD
UC San Diego Moores Cancer Center

Targeting PI3Kgamma and BTK to suppress tumor-associated inflammation

Judith Varner, PhD
UC San Diego Moores Cancer Center

CIRM 2.0. Building a better stem cell agency

C. Randal Mills
California Institute for Regenerative Medicine

Patient's Perspective

Theresa Blanda, Patient
Catriona Jamieson, MD, PhD, UC San Diego Moores Cancer Center

Combining VEGF inhibitors with strategies to manipulate the immune system in cancer

Napoleone Ferrara, MD
UC San Diego Moores Cancer Center

Development of Next Generation Angiogenesis Inhibitors

Charles Theuer, MD, PhD
TRACON Pharmaceuticals

Bringing Btk inhibition forward

Danelle James, MD, MAS

Reversing Drug Resistance in Cancer Stemness

David Cheresh, PhD
UC San Diego Moores Cancer Center

Preclinical and Clinical Cancer Stem Cell Detection and Elimination

Catriona Jamieson, MD, PhD
UC San Diego Moores Cancer Center

Symposium Organizers and Chairs

Symposium Organizers:

Scott Lippman, MD
UCSD Moores Cancer Center

Symposium Chair:

David Cheresh, PhD
Associate Director for Innovation and Industry Alliances,
Distinguished Professor of Pathology
UCSD Moores Cancer Center

Ida Deichaite, PhD
Director, Industry Relations
UCSD Moores Cancer Center

Symposium Co-Chair:

Catriona Jamieson, MD, PhD
Associate Professor of Medicine,
Chief, Division of Regenerative Medicine
Deputy Director, Sanford Stem Cell Clinical Center
Director, Moores Cancer Center Stem Cell Research Program UCSD Moores Cancer Center